More importantly, when combined with PD‐1/PD‐L1 immune checkpoint inhibitors, this treatment resulted in complete tumor regression in all experimental animals, further highlighting the promising clinical translation potential of targeting the 5‐HT signaling pathway [586]. This evidence concerns the gene CD274 and neoplasm.